Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TSR-033 |
Synonyms | |
Therapy Description |
TSR-033 is a humanized monoclonal antibody that targets LAG3 and inhibits binding of class II MHC molecules, potentially resulting in enhanced anti-tumor immune response, particularly in combination with other agents (PMID: 30587557). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TSR-033 | TSR033|TSR 033 | LAG3 Antibody 18 | TSR-033 is a humanized monoclonal antibody that targets LAG3 and inhibits binding of class II MHC molecules, potentially resulting in enhanced anti-tumor immune response, particularly in combination with other agents (PMID: 30587557). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03250832 | Phase I | TSR-033 TSR-033 + unspecified PD-1 antibody | Study of TSR-033 With an Anti-PD-1 | Completed | USA | FRA | 0 |